Pravastatin Shortage: What Providers and Prescribers Need to Know in 2026

Pravastatin remains one of the most-prescribed statins in the United States, with over 11 million prescriptions filled annually. As a cornerstone of dyslipidemia management and cardiovascular risk reduction, any supply disruption has direct implications for patient care. This briefing provides an evidence-based overview of Pravastatin's current supply status, prescribing considerations, therapeutic substitution guidance, and practical tools to help your patients maintain continuity of therapy.

Current Supply Status (2026)

As of 2026, Pravastatin is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortages Resource Center. There is no active national shortage. Pravastatin sodium has been available as a multi-source generic since April 2006, and the current market includes more than a dozen active generic manufacturers — including Teva, Zydus, Cipla, Glenmark, and Aurobindo. This robust manufacturer landscape provides substantial supply chain redundancy.

That said, localized pharmacy-level stock-outs can and do occur. Providers should be prepared to assist patients who report difficulty accessing their medication, even in the absence of a formal shortage designation.

Why Patients May Report Difficulty Finding Pravastatin

Despite stable national supply, individual pharmacy stock-outs arise for several reasons:

Lean inventory: Generic Pravastatin's thin profit margins mean pharmacies often order just-in-time rather than maintaining large buffers.

Strength-specific shortfalls: A specific manufacturer may temporarily reduce output of a particular strength (e.g., 10 mg or 80 mg) while other strengths remain plentiful.

Wholesaler disruptions: Distribution center delays or downstream logistics issues can create brief supply gaps at the pharmacy level.

Therapeutic Substitution: Dose Equivalency Guidance

If a patient cannot access Pravastatin, a therapeutic substitution to another statin may be appropriate. Pravastatin is classified as a low-to-moderate intensity statin. The 2018 AHA/ACC guidelines define statin intensity as follows:

Low intensity: Pravastatin 10–20 mg, Simvastatin 10 mg, Lovastatin 20 mg (expected LDL reduction < 30%)

Moderate intensity: Pravastatin 40–80 mg, Atorvastatin 10–20 mg, Rosuvastatin 5–10 mg, Simvastatin 20–40 mg (expected LDL reduction 30–50%)

High intensity: Atorvastatin 40–80 mg, Rosuvastatin 20–40 mg (expected LDL reduction ≥ 50%)

When substituting, match the patient's current intensity level rather than milligram dose. A patient on Pravastatin 40 mg (moderate intensity) would typically be switched to Atorvastatin 10–20 mg or Rosuvastatin 5–10 mg to maintain equivalent LDL-lowering effect.

Pravastatin's Unique Pharmacological Profile

When selecting a therapeutic substitute, note that Pravastatin has a distinct pharmacological profile that may be relevant for some patients:

Minimal CYP450 metabolism: Unlike Atorvastatin and Simvastatin (CYP3A4 substrates), Pravastatin undergoes minimal hepatic CYP450 metabolism. This significantly reduces its interaction potential with CYP3A4 inhibitors (azole antifungals, macrolides, HIV protease inhibitors, etc.).

Hydrophilic: As a hydrophilic statin, Pravastatin has limited penetration into non-hepatic tissues. This property is theorized to reduce myopathy risk compared to lipophilic statins, though clinical evidence is mixed.

Grapefruit: No clinically significant grapefruit juice interaction (unlike Lovastatin and Simvastatin, which are CYP3A4-metabolized).

OATP1B1 substrate: Pravastatin is transported by OATP1B1. Inhibitors of OATP1B1 (e.g., cyclosporine, gemfibrozil, certain HIV antiretrovirals) increase Pravastatin exposure and myopathy risk. Cyclosporine limits Pravastatin to a maximum 20 mg daily dose.

Special Populations: Considerations for Therapeutic Substitution

Transplant patients on cyclosporine: Pravastatin is often preferred because cyclosporine significantly elevates levels of many statins (Atorvastatin, Simvastatin) but has a less severe interaction with Pravastatin. If switching, review OATP1B1 interaction profile of the substitute statin carefully.

Patients on HIV antiretrovirals: Many HIV protease inhibitors interact with CYP3A4-metabolized statins. Pravastatin and Rosuvastatin are typically preferred in HIV patients on protease inhibitors, though HIV medication-specific guidance should be reviewed.

Pediatric patients: Pravastatin is FDA-approved for heterozygous familial hypercholesterolemia in patients as young as 8 years. If substituting in pediatric patients, verify FDA approval for the substitute statin in the appropriate age group.

How to Help Your Patients Access Pravastatin

When patients report that their pharmacy is out of Pravastatin, directing them to pharmacy-finding resources can save significant time and stress. medfinder for providers is a service that contacts pharmacies near a patient's location to check which ones have their medication in stock. Results are texted to the patient. This reduces calls to your office and helps patients maintain therapy continuity.

Key Takeaways for Providers

No national Pravastatin shortage exists as of 2026; localized stock-outs are a distribution issue, not a supply crisis.

If substitution is needed, match intensity level (not milligram dose) and account for Pravastatin's unique CYP450-independent metabolism.

For transplant patients and those on HIV antiretrovirals, Pravastatin's interaction profile may make substitution to another statin more complex — consult drug interaction databases before switching.

Counsel patients not to stop statin therapy without guidance, especially those with established ASCVD.

Related reading: How to Help Your Patients Find Pravastatin: A Provider's Guide | Pravastatin Shortage: Patient Update